Goodsurance

Drug prices & Part D

CMS Opens a New Database This Fall to Track Discounted Drugs Sold Through Medicare Part D

Starting October 1, 2026, safety-net health providers that buy drugs at a 340B discount can voluntarily report those Part D claims to CMS, filling a gap that has made it harder to enforce inflation rebate rules accurately.

By the Goodsurance editorial teamAugust 29, 2026

CMS released a companion guide and technical instructions in late August 2026 for a new Medicare Part D Claims Data 340B Repository, set to open for voluntary submissions on October 1, 2026.

The repository is tied to the Medicare Part D drug inflation rebate program. Under that program, drug manufacturers pay rebates to Medicare when they raise prices faster than inflation. Federal law, however, exempts drugs purchased through the 340B Drug Pricing Program from those rebate calculations. The 340B program allows qualifying safety-net hospitals, clinics, and health centers to buy certain outpatient drugs at steep discounts to serve low-income patients.

CMS opens a first-ever 340B drug data repository for Medicare Part D on October 1. Safety-net providers can start reporting voluntarily this fall.

Until now, CMS had no centralized system to identify which Part D drug claims were filled using 340B-priced inventory. The new repository closes that gap. Covered entities, or their designated third-party administrators, may submit relevant claims data directly to CMS on a quarterly schedule.

Data covering Part D claims with service dates from January through September 2026 is expected by December 31, 2026. CMS indicated it may consider mandatory reporting in the future, though no such requirement currently exists.

Safety-net providers in the 340B program collectively serve a disproportionate share of low-income and uninsured patients, many of whom also hold Medicare coverage.

In plain words

Some hospitals and clinics buy certain medicines at a lower price through a federal program called 340B. When those lower-cost medicines are used for Medicare Part D patients, they should not be counted the same way as regular drugs in a Medicare rebate program. CMS now has a new online system where these providers can report which Part D drug claims used the 340B discount. It opens October 1, 2026. Reporting is optional for now. This helps make sure the right amounts get calculated in Medicare drug rebate rules. Many of these providers serve low-income Medicare patients.

Source: 340B Report
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Comment Period Closes September 18 on How Drug Companies Must Apply Medicare-Negotiated Prices at Clinics and Doctor's Offices Starting in 2028

A CMS draft guidance describes the step-by-step process manufacturers must follow to make sure negotiated Medicare prices actually reach patients receiving infused or injected medicines at a doctor's office or outpatient clinic. Public comments are due September 18, 2026.

September 3, 2026

Drug prices & Part D

Medicare's Third Drug Negotiation Cycle Enters Its Final Month Before CMS Must Send Written Offers on 15 Drugs

CMS must issue final written maximum fair price offers to all 15 drug manufacturers in the third negotiation cycle by September 30. Companies then have until October 31 to accept or reject, with any agreed prices published by November 30 and taking effect in January 2028.

September 2, 2026

Drug prices & Part D

With Open Enrollment Weeks Away, Medicare Rights Center Recaps What the Inflation Reduction Act Has Delivered for Part D in 2026

An August 27 analysis from the Medicare Rights Center outlines the drug law's current protections, including a first-ever Part D out-of-pocket cap and ten negotiated drug prices that took effect in January.

August 30, 2026

Drug prices & Part D

Medicare Drug Plans Paid 587.7 Million Dollars for Prescriptions That Had Already Gone Over the Counter, OIG Finds

A federal audit found that from 2021 through 2023, Part D plans paid hundreds of millions of dollars for five drugs that had already switched from prescription-only to over-the-counter status, because CMS did not update its reference files quickly enough.

August 28, 2026

Drug prices & Part D

Federal Appeals Court Rejects Drug Manufacturer's Challenge to Medicare Price Negotiation Program

The U.S. Court of Appeals for the D.C. Circuit dismissed a pharmaceutical company's lawsuit arguing that the Medicare drug price negotiation program is unconstitutional, continuing a series of judicial losses for industry opponents of the program.

August 28, 2026

Drug prices & Part D

Noncovered Drug Versions Are Inflating What Medicare Pays for Certain Infused Medicines, Federal Watchdog Reports

OIG examined five quarters of Part B drug billing data and found that four of six drug billing codes had payment rates pushed up because CMS included the price of noncovered self-administered versions in its calculations.

August 26, 2026